Despite significant advances in cancer care over the past decade, stomach cancer remains one of the leading causes of cancer-related deaths worldwide. While surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy have improved outcomes for many patients, advanced or recurrent stomach cancer continues to present major treatment challenges.
Unfortunately, many patients eventually experience disease progression after standard treatments. In some countries, access to newly approved medicines, clinical trials, or innovative therapies may also be limited. As a result, an increasing number of patients are exploring stomach cancer treatment abroad in search of new hope and additional treatment options.
For many international patients, traveling overseas is no longer simply about lower costs—it is about gaining access to the latest medical innovations that may not yet be available in their home country.
Why China has become a destination for stomach cancer treatment
Over the past two decades, China has rapidly transformed into one of the world’s leading centers for cancer research, biotechnology, and precision medicine. Massive investment in biomedical innovation, world-class cancer hospitals, and an expanding clinical research network have accelerated the development of novel cancer therapies.
Today, China is home to hundreds of ongoing oncology clinical trials and has become a global leader in cellular immunotherapy, antibody-drug conjugates (ADCs), bispecific antibodies, and next-generation targeted therapies.
One of the most remarkable achievements is China’s leadership in developing CAR-T cell therapies for solid tumors—an area that has long been considered one of the greatest challenges in cancer treatment.
In 2026, China became the first country in the world to approve a CAR-T cell therapy for a solid tumor. The approval of Satri-cel (satri-cabtagene autoleucel, CT041) marked a historic milestone not only for China but also for global cancer treatment, providing a completely new treatment option for stomach cancer and gastroesophageal junction (GEJ) cancer expressing Claudin 18.2 (CLDN18.2).
For many patients seeking stomach cancer treatment for international patients in China, this breakthrough represents access to a therapy unavailable in most other countries.
Satri-cel: A breakthrough in CAR-T cell therapy for stomach cancer
Satri-cel is the world’s first approved CAR-T cell therapy for stomach cancer and other CLDN18.2-positive gastric and gastroesophageal junction cancers.
Unlike chemotherapy, which attacks rapidly dividing cells, CAR-T therapy uses the patient’s own immune cells. T cells are collected, genetically engineered to recognize the CLDN18.2 protein on cancer cells, expanded in the laboratory, and then infused back into the patient to target and destroy cancer cells more precisely.
Clinical studies have demonstrated encouraging anti-tumor activity in patients with advanced gastric cancer who had previously received multiple lines of treatment. The approval of Satri-cel has opened a new chapter in solid tumor immunotherapy and provides hope for patients whose treatment options have become limited.
Although not every patient is eligible, Satri-cel represents an important new treatment option for stomach cancer, particularly for patients with CLDN18.2-positive disease after standard therapies have failed.
As research continues, additional CAR-T therapies and combination treatment strategies are expected to further expand treatment possibilities for gastric cancer.
Comprehensive treatment options beyond CAR-T
While CAR-T cell therapy for stomach cancer has attracted global attention, it is only one part of a comprehensive treatment strategy.
Depending on the stage of disease, tumor biology, and the patient’s overall condition, specialists in China may recommend a personalized treatment plan that includes:
- Advanced laparoscopic or robotic surgery
- Chemotherapy
- Radiotherapy
- Targeted therapy
- Immunotherapy
- HER2-targeted therapy
- CLDN18.2-targeted antibody therapy
- Antibody-drug conjugates (ADCs)
- Clinical trials
- Nutritional and supportive care
- Multidisciplinary treatment planning
This multidisciplinary approach allows physicians to combine different therapies to achieve the best possible outcome for each individual patient.
Comprehensive services for international patients
Receiving stomach cancer treatment for international patients in China involves more than choosing a hospital. Patients also need guidance throughout the medical journey.
Our team works closely with leading cancer centers across China to help international patients access appropriate treatment and receive personalized support.
Services include:
- Free medical record review
- Expert second opinions
- Hospital and specialist matching
- Treatment planning before travel
- Medical visa assistance
- Professional medical interpretation
- Airport transfers and accommodation arrangements
- Ongoing patient coordination
- Follow-up after returning home
Whether you are seeking a second opinion, exploring stomach cancer treatment abroad, or looking for access to innovative therapies such as Satri-cel and CAR-T cell therapy for stomach cancer, we are committed to helping you understand your options and connect with experienced specialists in China.
China’s rapid advances in oncology and biotechnology are creating new possibilities for patients around the world. For many families, traveling abroad is no longer just about receiving treatment—it is about accessing tomorrow’s cancer therapies today.
